Type II Inflammation

Latest News

  Phase 3 Trial Points to Successful Treatment of Itch-Causing Condition — and Type 2 Inflammation as a Culprit
Phase 3 Trial Points to Successful Treatment of Itch-Causing Condition — and Type 2 Inflammation as a Culprit

November 3rd 2023

Nemolizumab quelled the itching caused by prurigo nodularis, a rare skin condition. By inhibiting interleukin-31, the experimental drug seems to have a downstream effect on other interleukins secreted during type 2 inflammation.

Atopic dermatitis on patient arm
Black/African American Patients With Atopic Dermatitis Report Improvements, Satisfaction on Dupixent

November 2nd 2023

Black pediatrician examining a boy sitting with his mother | Image credit: fizkes - stock.adobe.com
Long-Term Treatment With Dupixent Safe, Effective in Children With EoE

October 28th 2023

  In Type 2 Inflammation, an Unexpected Relationship Between Itchiness and Inflammation
In Type 2 Inflammation, an Unexpected Relationship Between Itchiness and Inflammation

October 26th 2023

Doctor examining Black boy's skin | Image credit: Pixel-Shot - stock.adobe.com
Children With AD Should Be Referred for Evaluation of Allergic Contact Dermatitis

October 10th 2023

More News

© 2024 MJH Life Sciences

All rights reserved.